These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 38491523)
1. Machine learning-driven prognostic analysis of cuproptosis and disulfidptosis-related lncRNAs in clear cell renal cell carcinoma: a step towards precision oncology. Chen R; Wu J; Che Y; Jiao Y; Sun H; Zhao Y; Chen P; Meng L; Zhao T Eur J Med Res; 2024 Mar; 29(1):176. PubMed ID: 38491523 [TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning. Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318 [TBL] [Abstract][Full Text] [Related]
3. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma. Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642 [TBL] [Abstract][Full Text] [Related]
4. Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma. Xu K; Li D; Ji K; Zhang Y; Zhang M; Zhou H; Hou X; Jiang J; Zhang Z; Dai H; Sun H Biol Direct; 2024 Aug; 19(1):71. PubMed ID: 39175011 [TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma. Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979 [TBL] [Abstract][Full Text] [Related]
6. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma. Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262 [TBL] [Abstract][Full Text] [Related]
7. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma. Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797 [TBL] [Abstract][Full Text] [Related]
8. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. Zhou L; Fang H; Guo F; Yin M; Long H; Weng G J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868 [TBL] [Abstract][Full Text] [Related]
9. Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer. Xu L; Wang S; Zhang D; Wu Y; Shan J; Zhu H; Wang C; Wang Q J Cancer Res Clin Oncol; 2023 Dec; 149(18):16511-16523. PubMed ID: 37712959 [TBL] [Abstract][Full Text] [Related]
10. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma. Li X; Deng X; Liu T; Zhang W; Tao J Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964 [TBL] [Abstract][Full Text] [Related]
11. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792 [TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma. Shen J; Wang L; Bi J BMC Cancer; 2023 Feb; 23(1):160. PubMed ID: 36797708 [TBL] [Abstract][Full Text] [Related]
13. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910 [TBL] [Abstract][Full Text] [Related]
14. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer. Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096 [TBL] [Abstract][Full Text] [Related]
15. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H Front Genet; 2022; 13():938259. PubMed ID: 35910212 [No Abstract] [Full Text] [Related]
17. A new perspective: deciphering the aberrance and clinical implication of disulfidptosis signatures in clear cell renal cell carcinoma. Chen B; Zhou M; Guo L; Sun X; Huang H; Wu K; Chen W; Wu D Aging (Albany NY); 2024 Jun; 16(11):10033-10062. PubMed ID: 38862242 [TBL] [Abstract][Full Text] [Related]
18. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data. Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717 [TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs. Wei M; Lu L; Luo Z; Ma J; Wang J BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Pan Y; Zhang Q; Zhang H; Kong F Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]